2-(6-Hydroxy-1,3-Benzothiazol-2-Yl)-4,5-Dihydro-1,3-Thiazole-4-Carboxylic Acid

In vivo bioluminescence imaging protocols relying on firefly luciferase reporters demand substrate preparations that maintain optical signal stability over extended acquisition windows without inducing acute haemodynamic disturbances in rodent models. The sodium or potassium salt of 2-(6-hydroxy-1,3-benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid is formulated as a sterile-filtered solution at concentrations of 15–30 mg/mL in Dulbecco’s phosphate-buffered saline (DPBS) adjusted to pH 7.4, with phosphate molarity clamped at 10–50 mM to mimic physiological osmolarity. Industry-level compliance for any injectable-grade luciferin substrate adheres to USP <42> bacterial endotoxins testing (limit ≤ 0.5 EU/mg), USP <1> injections, and the biocompatibility evaluation series ISO 10993-1:2018, particularly when the formulated product is intended for repeat-dose pharmacokinetic imaging in animals that generate data for IND-enabling studies under FDA 21 CFR Part 58 (Good Laboratory Practice). Production-scale lyophilisation cycles executed in Class 100 isolators typically begin with a freezing ramp to -45 °C over 120 min, primary drying at -20 °C and 50–80 µbar for 18–24 h, and secondary drying at 25 °C at ≤ 10 µbar; the product is backfilled with argon to retard oxidative dimerization of the 6-hydroxybenzothiazole chromophore into dehydrogenated by-products that elevate background bioluminescence. Each batch is released with ≥ 99.5 % purity by HPLC (C18, 330 nm detection) and residual moisture below 1.5 %. The terminal dosage form is a 250 mg or 1 g lyophilised powder in a 20 mL amber Type I borosilicate vial sealed under argon, accompanied by a separate 10 mL diluent ampoule of endotoxin-free DPBS. Reconstitution yields a stock at 30 mg/mL, which is diluted with warmed 37 °C diluent immediately prior to intraperitoneal or intravenous administration at a body-weight-adjusted dose of 150 mg/kg. On-board spectral unmixing algorithms in instruments such as the IVIS Spectrum CT (PerkinElmer) require emission profiles to remain centred at 560 ± 10 nm with minimal red-shift, a specification that demands strict exclusion of heavy-metal cations from all contact surfaces and the addition of 0.1 mM EDTA to the reconstitution buffer.

What Defines Luminescence Decay Half-Life in ATP-Driven Hygiene Monitoring Reagents?

Adenosine triphosphate bioluminescence testing for surface cleanliness in food processing and healthcare facilities depends on a reagent cocktail in which the luciferin substrate constitutes 0.4–0.8 mM of the reconstituted solution, corresponding to 0.12–0.24 mg of free acid equivalent per swab eluate. Compliance for hygiene monitoring kits sold into EU markets is structured around EU Regulation 1935/2004 for food contact materials and the ATP hygiene monitoring guidance embedded in ISO 22000:2018 clause 8.2.4, while water microbiological testing references ASTM D4012-15 “Standard Test Method for Adenosine Triphosphate in Water.” The downstream manufacturing process for stabilized liquid reagents proceeds by dissolving the lyophilised luciferin intermediate into a 50 mM Tris-acetate buffer (pH 7.75) containing 2 mM dithiothreitol, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5 mM magnesium acetate, holding the blend under a nitrogen blanket at 4 °C during a 120-minute brightness maturation step before sterile filtration through a 0.22 µm polyethersulfone membrane. A critical operational boundary arises from the pH sensitivity of the luciferin–luciferase kinetics: if the formulated reagent drifts above pH 8.0 during storage, the quantum yield decays by approximately 12% per 0.1 pH unit due to non-enzymatic hydrolytic ring-opening of the thiazoline carboxylate. To suppress this drift, commercially supplied liquid-stable ATP detection reagents are dispensed into 2 mL opaque polyethylene snap-cap vials under a positive-pressure nitrogen headspace and subjected to accelerated stability testing at 37 °C over 28 days per ISO 23666:2022. Terminal kit configurations include single-service swab devices pre-wetted with an extraction surfactant that lyses somatic ATP, paired with a separate enzyme–substrate cuvette delivering a limit of detection of ≤ 1 fmol ATP (equivalent to ≈ 500 bacterial CFU). In high-sensitivity water testing modules compliant with the heterotrophic plate count correlation requirements of ASTM D4012-15, a concentrated luciferin stock at 2 mg/mL in glycerol is manually spiked into a luminometer tube immediately before sample injection to overcome the luminescence quenching effect of dissolved humic acids present in surface water matrices at concentrations above 2 ppm.

Dual-Luciferase Reporter Substrate Formulation Under High-Throughput Screening Pressure

Firefly luciferase reporter assays harnessed for drug discovery and functional genomics demand a substrate buffer where the D-luciferin concentration is held at 0.5–1.0 mM together with 1.25 mM ATP, 15 mM MgSO₄, 33.3 mM dithiothreitol, and 0.1 mM Coenzyme A in a 25 mM Tricine buffer (pH 7.8). All formulations intended for use in stable cell lines carrying dual-luciferase constructs (firefly + Renilla) are validated under ICH Q2(R2) for linearity, precision, and intermediate reproducibility, with particular attention to lot-to-lot luminescence CV remaining below 5% across 384-well plate formats. Manufacture of the complete “firefly substrate mix” proceeds under yellow-light cleanroom conditions in a building classified as ISO 14644-1 Class 7; the lyophilised luciferin is dissolved in cell-culture-grade Water for Injection and combined with the remaining components through a sequence of compounding vessel additions where dissolved oxygen is continuously purged with argon at 0.5 L/min and monitored with an optical O₂ probe set to alarm above 50 ppb. A process conflict emerges when the viscous Coenzyme A stock, pre-adjusted to pH 5.0 to avoid disulfide cleavage, is injected into the alkaline main blend: local pH excursions above 8.2 at the injection point can deaminate CoA within seconds, and this is mitigated by a static mixer immediately downstream of the CoA injection port, reducing contact time to less than 5 seconds. Post-filtration, the reagent is dispensed through a peristaltic pump with 0.8 mm PharMed tubing into 10 mL LDPE-amber screw-cap bottles and immediately capped under an argon sweep. Terminal shelf-life is assigned at 12 months at -20 °C based on real-time stability data collected per ISO 23666:2022. The final commercial product is a “Firefly Detection Reagent II,” shipped on dry ice, intended for direct addition to cell lysates in agonist dose-response experiments on G-protein-coupled receptor targets, with a recommended 100 µL volume per well of a 96-well white opaque plate, generating integration times of 0.5–2.0 seconds on plate readers equipped with photon-counting photomultiplier tubes.

Real-time pyrosequencing for microbial identification and resistance allele calling incorporates the luciferin substrate into an enzyme mixture that also includes ATP sulfurylase, firefly luciferase, apyrase, and adenosine 5′-phosphosulfate. The formulated reagent, often referred to as “PyroMark Sequencing Mix,” maintains D-luciferin at 0.3–0.5 mg/mL in a glycerol-containing stock that is diluted 1:10 into the reaction cartridge just prior to cyclic nucleotide dispensation. Compliance with IVD Regulation (EU) 2017/746 for diagnostic sequencing assays requires demonstration that substrate activity remains within ± 15 % of the certified reference value throughout the on-instrument residence time of 8 hours at 28 °C, which is verified by monitoring light emission triggered by a 10 pmol ATP standard pulse at the start and end of each sequencing run. Production of the lyophilised or frozen sequencing enzyme–substrate blend is carried out in a dedicated Class C cleanroom where all glassware is pre-treated with 1 M HCl and rinsed with DEPC-treated water to eliminate adventitious ATP originating from skin squames and bacterial contamination; residual ATP in bulk buffer is driven below 0.01 fmol/µL through pre-incubation with apyrase immobilized on agarose beads and subsequently removed by tangential flow filtration across a 100 kDa polyethersulfone cassette. The terminal configuration is a single-use freeze-dried bead containing 1.2 µg luciferin, 0.8 U firefly luciferase, 2 mU ATP sulfurylase, and proprietary stabilizers, sealed into an 8-strip cartridge foil pouch under 0.5% residual oxygen. Incompatibilities arise when amine-based additives or high concentrations of sulfate ions (> 50 mM) are introduced into the sample preparation stream, as these species competitively inhibit the ATP sulfurylase active site and cause a progressive decrease in peak height ratios for sequential nucleotide flows; users of the pyrosequencing platform are therefore instructed to avoid all phosphate-saline buffers containing ammonium sulfate in the upstream PCR purification step. Each manufactured lot is evaluated with a standardized genomic DNA template bearing a heterozygous SNP, and the pass criterion is a peak-height difference below 5% between the expected and observed heterozygous alleles measured on a PyroMark Q48 instrument.

When 3D Spheroid Models Reduce ATP Availability — Substrate Interplay in Cell Viability Readouts

ATP-based cell viability determination using luciferin–luciferase chemistry in three-dimensional tumour spheroids and organoid cultures has revealed a concentration-dependent quenching phenomenon that is absent in monolayer assays. In homogeneous “add-mix-read” formats such as the CellTiter-Glo 3D protocol, the working reagent carries luciferin at 0.5 mM after a 1:1 dilution with culture medium, but spheroids exceeding 400 µm in diameter generate a hypoxic core where extracellular ATP concentrations fall below 0.1 nM, necessitating a substrate amplification step that raises the effective luciferin concentration to 1.2 mM to maintain signal linearity across the dynamic range. Quality requirements for such reagents align with ISO 10993-5:2009 (in vitro cytotoxicity) when endpoints are used for biocompatibility assessment of medical device extracts, and with USP <1031> for biological assay validation when data support compendial potency tests. The industrial manufacture of the corresponding single-solution viability reagent starts with heating WFI to 80 °C to inactivate any endogenous ATP-degrading enzymes, followed by rapid cooling to 4 °C and addition of dry luciferin powder under high-shear mixing at 3500 rpm for 20 min to ensure complete dissolution without localized overheating that could trigger decarboxylation. A critical processing window exists for the pH adjustment step: sodium hydroxide is metered in as a 0.2 M solution at a rate not exceeding 1 mL/min per litre of bulk, because a transient rise to pH 9.2 at the titrant inlet accelerates oxidative degradation of the benzothiazole thiol to a disulfide dimer that acts as a luciferase inhibitor. The finished reagent is aliquoted into 100 mL PETG bottles with a headspace purged by medical-grade nitrogen and stored at -70 °C, achieving a stated shelf-life of 36 months with less than 10% loss of integrated luminescence intensity. The final product, a “3D Viability Detection Mix,” is designed to lyse complex 3D architectures within 5 min at ambient temperature and is validated on U-bottom ultra-low-attachment plates using HCT116 colorectal carcinoma spheroids with a Z´-factor exceeding 0.7.

Water-Contamination Early Warning Panels and the Critical ATP Extraction Step

Real-time bioburden monitoring in pharmaceutical water loops and cooling towers employs disposable luciferin–luciferase kits whose analytical sensitivity is determined by the ATP extraction efficiency from Gram-negative and Gram-positive vegetative cells as well as bacterial endospores. The substrate contribution in the final luminescence cuvette is pinned at 0.25 mg/mL luciferin in a lyoprotectant matrix containing 2.5 % (w/v) raffinose and 0.1 % polyvinylpyrrolidone, freeze-dried onto the bottom of a 6 mm polystyrene tube. Methodological harmonisation is achieved through compliance with ASTM D4012-15 Section 13 for direct ATP measurement in potable and process water, supplemented by the internal quality control plan of ISO 7704:2023 (Water quality — Requirements for the performance of test kits for the enumeration of culturable microorganisms). The downstream manufacture of the ATP release-and-read single-step device confronts a compatibility conflict: the lytic agent benzalkonium chloride at 0.02 % efficiently extracts somatic ATP but simultaneously denatures the luciferase if co-lyophilised without spatial segregation. This is resolved by depositing the luciferin–enzyme lyocake in the tube base and spraying a microfilm of the quaternary ammonium detergent onto the interior cap surface, separated by a sintered polyethylene frit that dissolves only upon sample addition. Processing is performed on a rotary lyophilisation line operating at a condenser temperature of -85 °C and chamber pressure of 30 µbar, with a primary drying plateau at -10 °C for 16 h; the hermetic sealing of tubes with a crimped aluminium cap imparts a moisture vapor transmission rate of ≤ 0.005 g/unit/day. The finished consumable is sold as a “Microbial ATP Detection Tube” with a certified detection limit of 0.5 pg ATP (equivalent to ≈ 1,000 bacterial cells) and a quantitation range spanning 3 log₁₀ units. Lot release testing relies on a challenge panel of ATP-negative purified water spiked with a 1,000 CFU/mL suspension of Pseudomonas fluorescens ATCC 13525; the relative light unit output must fall within 85–115 % of the reference lot’s calibration curve established on a Hygiena EnSURE Touch luminometer. Users are advised that oxidising biocides such as chlorine dioxide above 0.5 ppm residual concentration in the sampled water chemically degrade the benzothiazole ring system, producing an irreversible signal loss that cannot be corrected by standard addition, mandating a thiosulfate neutralisation step prior to sample injection.